Dynavax technologies corp (DVAX)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Operating activities
Net loss

-152,600

-158,899

-95,154

-112,444

-106,794

-90,722

-66,720

-69,949

-48,597

-57,308

-30,565

Adjustments to reconcile net loss to net cash used in operating activities:
Consideration paid in excess of carrying value of the noncontrolling interest in SDI

-

-

-

-

-

-

-

-

-

-

19,671

Amount attributed to noncontrolling interest in SDI

-

-

-

-

-

-

-

-

-

-

-4,233

Depreciation and amortization

8,900

3,600

3,200

2,257

1,365

1,404

1,327

1,207

1,303

1,415

1,857

Amortization of right-of-use assets

3,375

-

-

-

-

-

-

-

-

-

-

Write-off of assets in progress

-

-

-

862

-

-

-

-

-

-

-

Loss (gain) on disposal of property and equipment

-18

-98

10

-91

-46

24

-18

-8

-20

36

-12

Accretion of discounts on marketable securities

1,462

1,559

193

-178

-660

-881

-923

-1,298

-1,172

-367

-4

Change in fair value of warrant liability

7,500

-

-

-

-

-

-

-

-

-

-

Reversal of deferred rent upon lease amendment

-

-

209

-

-

-

-

-

-

-

-

Fair value adjustment of the warrant and contingent liabilities to Holdings, including the impact of the anti-dilution provision associated with the common stock and warrants issued to Symphony Capital Partners, L.P. and Symphony Strategic Partners, LLC (collectively, "Symphony")

-

-

-

-

-

-

-

-

843

-8,816

-

Unoccupied facility expense

-

-

-

-

-

386

926

-

-

-

-

Interest associated with long-term note payable to Symphony Dynamo Holdings LLC (Holdings")

-

-

-

-

-

-

-

2,190

1,871

1,597

-

Accretion of debt discount related to debt financing

-

-

-

-

-115

-

-

-

-

-

-

Cash-settled portion of stock compensation expense

-

-

-

602

387

0

-

-

-

-

-

Interest associated with Deerfield financing agreement

-

-

-

-

-

-

-

-

-

-

84

Stock compensation expense

25,456

23,478

14,917

14,126

9,316

6,089

12,340

10,439

5,189

2,410

3,035

Cost of sales - amortization of intangible assets

9,217

10,862

1,194

-

-

-

-

-

-

-

-

Non-cash interest expense

4,973

2,755

-

-

-

-

-

-

-

-

-

Tenant improvements provided by the landlord

-6,999

-

-

-

-

-

-

-

-

-

-

Amortization of intangible assets

-

-

-

-

-

-

-

-

299

980

980

Loss on extinguishment of debt

-

-

-

-

-1,671

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts and other receivables, net

5,182

2,850

-488

-52

667

-900

622

-8,522

8,526

106

-5,512

Inventories, net

22,310

18,710

312

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

1,278

2,405

1,830

-560

-1,631

2,683

-677

922

-230

774

-405

Other assets

-1,632

3,706

936

103

-

-

-

-

-

-

-

Restricted cash and other assets

-

-

-

-

211

-277

-176

116

290

38

13

Accounts payable

4,848

3,417

-1,915

1,181

1,246

-523

-657

126

-289

643

781

Lease liabilities

2,000

-

-

-

-

-

-

-

-

-

-

Accrued liabilities and other liabilities

-9,376

12,597

3,198

-11,759

9,017

4,810

-2,291

1,916

-2,167

3,381

762

Deferred revenues

-

-

-

-2,654

-

-

-

-

-

-

-

Deferred revenues

-

-

-

-

-10,111

5,467

-4,770

1,472

3,512

-12,717

-31,844

Net cash used in operating activities

-121,252

-131,301

-77,518

-107,051

-92,559

-73,738

-58,673

-43,809

-47,116

-51,370

-33,552

Investing activities
Acquisition of technology licenses

7,000

11,000

-

-

-

-

-

-

-

-

-

Change in investments held by SDI

-

-

-

-

-

-

-

-

-

-

5,041

Purchases of marketable securities

215,191

213,804

227,672

126,754

208,936

44,807

192,044

206,149

111,205

80,835

14,289

Proceeds from maturities and redemptions of marketable securities

201,810

284,457

119,638

220,760

130,110

137,071

142,321

169,387

77,729

30,750

29,500

Purchases of property and equipment, net

22,401

4,187

669

7,757

6,970

1,667

1,629

2,931

1,142

420

377

Net cash provided by investing activities

-42,782

55,466

-108,703

86,249

-85,796

90,597

-51,352

-39,693

-34,618

-50,505

19,875

Financing activities
Proceeds from exercise of warrants

-

-

-

-

228

163

-

-

0

-

-

Proceeds from long-term debt, net

74,250

99,000

-

-

-

9,559

-

-

-

-

-

Proceeds from issuance of common stock, net

65,948

-

185,936

-

183,897

-

80,856

71,780

91,298

-

-

Proceeds from issuances of preferred stock, net

13,586

-

-

-

-

-

44,209

-

-

-

-

Cash acquired from the purchase of noncontrolling interest in SDI

-

-

-

-

-

-

-

-

-

-

19,732

Proceeds from issuances of common stock and warrants, net of issuance costs

-

-

-

-

-

-

-

-

-

87,399

2,242

(Tax withholding) from exercise of stock options and restricted stock awards, net

2

-523

1,613

-84

-

-

112

1,955

10

160

13

Payment of debt

-

-

-

-

10,988

-

-

-

-

-

-

Proceeds (withholding) from exercise of stock options and restricted stock awards, net

-

-

-

-

531

49

-

-

-

-

-

Proceeds from Employee Stock Purchase Plan

565

594

293

615

291

130

224

307

132

72

72

Net cash provided by financing activities

154,351

99,071

187,842

531

173,959

9,901

125,401

59,042

91,440

87,631

22,059

Payment of notes payable to Holdings

-

-

-

-

-

-

-

15,000

-

-

-

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-184

-482

701

-259

-303

-371

147

118

-218

-23

235

Net (decrease) increase in cash, cash equivalents and restricted cash

-9,867

22,754

2,322

-20,530

-4,699

26,389

15,523

-24,342

9,488

-14,267

8,617

Supplemental disclosure of cash flow information
Cash paid during the period for interest

12,147

6,583

-

-

-

-

-

-

-

-

-

Cash paid during the period for interest

-

-

-

-

720

-

-

-

-

-

-

Accrual for litigation settlement and insurance recovery (Note 9)

-

-

-

4,975

-

-

-

-

-

-

-

Release of accrual for litigation settlement and insurance recovery

-

-

4,975

-

-

-

-

-

-

-

-

Non-cash investing and financing activities:
Note payable issued to Holdings from purchase option exercised under the SDI collaboration

-

-

-

-

-

-

-

-

-

-

9,342

Liability from program option exercised under the SDI collaboration

-

-

-

-

-

-

-

-

-

-

15,000

Warrants issued in conjunction with the SDI transaction

-

-

-

-

-

-

-

-

-

6,638

1,764

Modification of warrants previously issued to Deerfield

-

-

-

-

-

-

-

-

-

-

84

Disposal of fully depreciated property and equipment

-

-

-

2,354

1,436

841

86

169

1,181

42

1,215

Non-cash acquisition of technology license

-

12,773

-

-

-

-

-

-

-

-

-

Purchases of property and equipment, not yet paid

2,698

920

378

-

-

-

-

-

-

-

-

Proceeds allocated to warrant liability at issuance

7,360

-

-

-

-

-

-

-

-

-

-

Right-of-use assets obtained in exchange for operating lease liabilities

40,626

-

-

-

-

-

-

-

-

-

-

Net change in unrealized (loss) gain on marketable securities

-

-

-

-

11

32

-76

48

14

-17

-

Astra Zeneca
Return of unused development funding to AstraZeneca AB

-

-

-

7,200

-

-

-

-

-

-

-

Milestone payment from AstraZeneca AB

-

-

-

7,200

-

-

-

-

-

-

-